论文部分内容阅读
目的探讨宫颈癌组织中FHIT与PTEN基因的表达及与临床组织病理特点的关系。方法采用免疫组织化学SP法检测50份宫颈癌组织(宫颈癌组)、50份宫颈上皮内瘤变组织(CIN组)及50份正常宫颈组织(对照组)中FHIT与PTEN的表达情况,分析其与宫颈癌临床组织病理特点的关系。结果宫颈癌组、CIN组及对照组FHIT蛋白阳性表达率分别为22%、64%、98%,PTEN蛋白阳性表达率分别为34%、78%、100%,宫颈癌组FHIT、PTEN表达与对照组和CIN组比较差异有统计学意义(P<0.05);宫颈癌组FHIT与PTEN的表达在临床FIGO分期、分化程度及组织病理类型上差异无统计学意义(P>0.05)。结论 FHIT、PTEN发生在宫颈癌变早期,联合检测有助于宫颈癌的早期诊断。
Objective To investigate the expression of FHIT and PTEN in cervical cancer and its relationship with clinicopathological features. Methods Immunohistochemical SP method was used to detect the expression of FHIT and PTEN in 50 cervical cancer tissues (cervical cancer group), 50 cervical intraepithelial neoplasia (CIN group) and 50 normal cervical tissues (control group) Its relationship with clinical histopathological features of cervical cancer. Results The positive expression rates of FHIT protein in cervical cancer group, CIN group and control group were 22%, 64%, 98%, respectively. The positive rates of PTEN protein were 34%, 78%, 100% The difference between the control group and CIN group was statistically significant (P <0.05). The expression of FHIT and PTEN in cervical cancer group had no statistical significance in FIGO staging, differentiation and histopathological types (P> 0.05). Conclusions FHIT and PTEN occur in the early stage of cervical cancer. Combined detection may be helpful for the early diagnosis of cervical cancer.